PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-26.20%
Negative net income growth while TRVN stands at 51.82%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.65%
Some D&A expansion while TRVN is negative at -7.69%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-4.67%
Both cut yoy SBC, with TRVN at -42.97%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-515.11%
Both reduce yoy usage, with TRVN at -125.24%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.40%
Some yoy usage while TRVN is negative at -125.24%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-12704.62%
Both negative yoy, with TRVN at -13.88%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-57.07%
Negative yoy CFO while TRVN is 26.33%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-196.22%
Both yoy lines negative, with TRVN at -7633.33%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-196.22%
Both yoy lines negative, with TRVN at -259.08%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Stock issuance far above TRVN's 32.41%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.